Premieră în lupta cu cancerul: un vaccin personalizat Moderna-Merck a redus riscul de recidivă și de metastaze în melanom, într-un studiu de fază 3

A personalized anti-cancer vaccine developed by Moderna and Merck has shown promising results in reducing melanoma recurrence risk in a phase 3 clinical trial. The study involved over 1,100 patients and demonstrated that the vaccine, tailored to individual tumor characteristics, can enhance the effectiveness of existing immunotherapy. While the results are encouraging, the vaccine remains experimental and is not yet available for patients. Further data will be presented to regulatory authorities for potential approval.